(3R)-5-氧代-3-[(四氢-2H-吡喃-2-基)氧基]-1-环戊烯-1-庚酸甲酯 | 60934-42-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: (3R)-5-氧代-3-[(四氢-2H-吡喃-2-基)氧基]-1-环戊烯-1-庚酸甲酯
• 英文名称: (4R)-2-(6-methoxycarbonylhexyl)-4-(tetrahydropyran-2-yloxy)cyclopent-2-enone
• 英文别名: 7-{5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]cyclopent-1-en-1-yl}heptanoic acid methyl ester；methyl 7-[3R-(tetrahydropyran-2-yloxy)-5-oxocyclopent-1-enyl] heptanoate；2-(6'-carbomethoxyhexyl)-4α-(tetrahydropyranyloxy)-cyclopent-2-enone；4(R)-Tetrahydropyranyloxy-2-(6-carbomethoxyhexyl)-cyclopent-2-en-1-one；Methyl 7-((3R)-5-oxo-3-((tetrahydro-2H-pyran-2-yl)oxy)cyclopent-1-en-1-yl)heptanoate；methyl 7-[(3R)-3-(oxan-2-yloxy)-5-oxocyclopenten-1-yl]heptanoate
• CAS: 60934-42-1
• 化学式: C₁₈H₂₈O₅
• 分子量: 324.417
• InChiKey: RMSROFOPTSOXCN-BUSXIPJBSA-N

物化性质

• 沸点：
  451.9±45.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  (3R)-5-氧代-3-[(四氢-2H-吡喃-2-基)氧基]-1-环戊烯-1-庚酸甲酯 在 溶剂黄146 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 24.0h， 以88%的产率得到(R)-(+)-3-羟基-5-氧代-1-环戊烯-1-庚酸甲酯
  参考文献：
  名称：

  Gill, Melvyn; Rickards, Rodney W., Australian Journal of Chemistry, 1981, vol. 34, # 5, p. 1063 - 1071

  摘要：

  DOI：
• 作为产物：
  描述：

  3,4-二氢-2H-吡喃 、 (R)-(+)-3-羟基-5-氧代-1-环戊烯-1-庚酸甲酯 在 对甲苯磺酸一水合物 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 (3R)-5-氧代-3-[(四氢-2H-吡喃-2-基)氧基]-1-环戊烯-1-庚酸甲酯
  参考文献：
  名称：

  16,16-Spirocycloalkyl prostaglandin derivatives

  摘要：

  这份披露描述了新颖的15-羟基-16,16-螺环烷基前列腺酸及其衍生物和同系物，它们可用作支气管扩张剂和胃酸分泌抑制剂。

  公开号：

  US04028396A1

文献信息

• Preparation of 15-deoxy-16-hydroxyprostaglandins
  申请人：Miles Laboratories, Inc.

  公开号：US04132738A1

  公开（公告）日：1979-01-02

  Analogues of PGE.sub.1 having the structural formula, ##STR1## in which J is R-hydroxymethylene or S-hydroxymethylene; R.sub.1 is hydrogen; R.sub.2 is hydrogen or together with R.sub.4 is a methylene chain of 2 to 3 carbon atoms such that a cycloalkyl of 5 to 6 carbon atoms inclusive is formed; R.sub.3 is hydrogen or methyl, or together with R.sub.4 is a methylene or a lower alkylated methylene chain of 2 to 5 carbon atoms such that a cycloalkyl or a lower alkylated cycloalkyl of 4 to 7 carbon atoms inclusive is formed, or together with R.sub.4 is bicycloalkyl or bicycloalkenyl moiety having the formula: ##STR2## SUCH THAT A BICYCLOALKYL OR BICYCLOALKENYL COMPOUND IS FORMED, WHEREIN M AND N ARE INTEGERS HAVING A VALUE FROM 0 TO 3, P IS AN INTEGER HAVING A VALUE FROM 0 TO 4 AND Q IS AN INTEGER HAVING A VALUE OF FROM 1 TO 4 AND WHEREIN THE DOUBLE BOND OF SUCH BICYCLOALKENYL IS IN THE M, N, P, OR Q BRIDGE; R.sub.4 is hydrogen or methyl or together with R.sub.2 or R.sub.3 forms a cycloalkyl or bicycloalkyl or bicycloalkenyl as defined above, or together with R.sub.5 is a methylene chain of 3 to 5 carbon atoms such that a cycloalkyl of 4 to 6 carbon atoms inclusive is formed; R.sub.5 is selected from the group consisting of hydrogen, straight-chain alkyl having from 1 to 3 carbon atoms or together with R.sub.4 forms a cycloalkyl as defined above; and R.sub.6 is hydrogen or straight-chain alkyl having from 1 to 3 carbon atoms are disclosed. Pge.sub.1 ester analogues of the above formula, limited to the structures wherein two of R.sub.2, R.sub.3 R.sub.4 and R.sub.5 form a cycloalkyl, lower alkylated cycloalkyl, bicycloalkyl or bicycloalkenyl are also disclosed. The prostaglandin analogues selectively produce bronchodilation and decrease gastric secretion in vivo. Methods of preparing the analogues and starting materials required in the synthesis of the analogues are also disclosed.

  具有结构式##STR1##的PGE.sub.1的类似物，其中J是R-羟甲亚甲基或S-羟甲亚甲基；R.sub.1是氢；R.sub.2是氢或与R.sub.4一起是2到3个碳原子的亚甲基链，形成包括5到6个碳原子的环烷基；R.sub.3是氢或甲基，或与R.sub.4一起是2到5个碳原子的亚甲基或低烷基化亚甲基链，形成包括4到7个碳原子的环烷基或低烷基化环烷基，或与R.sub.4一起是具有式子的双环烷基或双环烯基基团：##STR2##形成双环烷基或双环烯基化合物，其中M和N是具有值从0到3的整数，P是具有值从0到4的整数，Q是具有值从1到4的整数，且此类双环烯基的双键位于M、N、P或Q桥上；R.sub.4是氢或甲基，或与R.sub.2或R.sub.3一起形成如上定义的环烷基或双环烷基或双环烯基，或与R.sub.5一起是3到5个碳原子的亚甲基链，形成包括4到6个碳原子的环烷基；R.sub.5选自由氢、具有1到3个碳原子的直链烷基或与R.sub.4一起形成如上定义的环烷基；R.sub.6是氢或具有1到3个碳原子的直链烷基。上述结构的Pge.sub.1酯类似物，限于其中两个R.sub.2、R.sub.3、R.sub.4和R.sub.5形成环烷基、低烷基化环烷基、双环烷基或双环烯基的结构也被披露。这些前列腺素类似物在体内选择性地产生支气管扩张并减少胃分泌。还披露了制备这些类似物以及合成这些类似物所需的起始物料的方法。
• 1 And 2-substituted analogues of certain prostaglandins
  申请人：Miles Laboratories, Inc.

  公开号：US04171331A1

  公开（公告）日：1979-10-16

  Disclosed are trans 1 & 2-di(loweralkyl)phosphono; 1 & 2-chloro, bromo and iodo; 1 & 2-thio and 1 & 2-amino analogues of E.sub.1, A.sub.1, F.sub.1.alpha., F.sub.1.beta., 11 deoxy E.sub.1, 11 deoxy F.sub.1.beta., and 11 deoxy F.sub.1.alpha. prostaglandins. The prostaglandins of this invention are variously useful as antithrombic agents, bronchodilators such as in the treatment of asthma, inhibitors of gastric secretion and as antihypertensive agents. Certain of the prostaglandins disclosed herein are useful as precursors for prostaglandins having one or more of the foregoing utilities.

  本发明公开了E.sub.1、A.sub.1、F.sub.1.alpha.、F.sub.1.beta.、11去氧E.sub.1、11去氧F.sub.1.beta.和11去氧F.sub.1.alpha.前列腺素的trans 1和2-二(较低烷基)膦酸酯；1和2-氯、溴和碘；1和2-硫和1和2-氨基类似物。本发明的前列腺素可用作抗凝血剂、支气管扩张剂（如治疗哮喘）、胃酸分泌抑制剂和降压剂。本文所披露的某些前列腺素可用作具有上述一种或多种用途的前列腺素的前体。
• 7-{3-Hydroxy-2-[4-hydroxy-4-(lower
  申请人：G. D. Searle & Co.

  公开号：US04060691A1

  公开（公告）日：1977-11-29

  7-3-Hydroxy-2-[4-hydroxy-4-(lower alkyl)-trans-1-octen-1-yl]-5-oxocyclopent-1-ylheptanoic acids and esters, displaying valuable pharmacological properties, e.g., gastric anti-secretory, are produced by the reaction of a 7-(3-oxygenated-5-oxocyclopent-1-en-1-yl)heptanoic acid or ester with the appropriate organometallic reagent.

  通过将7-(3-氧化-5-氧代环戊烯-1-基)庚酸或酯与适当的有机金属试剂反应，可以生产出具有有价值药理学特性（例如胃抗分泌）的7-3-羟基-2-[4-羟基-4-(低碳基)-反-1-辛烯-1-基]-5-氧代环戊-1-基}庚酸和酯。
• Cyclopentenone and cyclopentenol derivatives and processes for their preparation
  申请人：THE AUSTRALIAN NATIONAL UNIVERSITY

  公开号：EP0009892A1

  公开（公告）日：1980-04-16

  Compounds of the general formula I are disclosed as useful intermediates in the preparation of prostanoids: wherein A represents 0 or H, ORz; Rz represents hydrogen or a protecting group; Rx represents hydrogen or a protecting group; and Ry represents halogen, a substituted thio group, di-substituted amino group, or a group of the formula R2, and R2 represents a straight-or branched-chain alkyl, alkenyl or alkynyl group which may optionally be substituted by one or more carboxyl, carboxylic acid ester, or free or protected hydroxyl, thiol, aldehyde or keto groups; with the provisos that Rx is not hydrogen when A is O and Ry is R2; and that when A is H, ORz RY is R2 and RX and Rz are not both hydrogen. Processes forthe preparation of these compounds and of 2-substituted 4-hydroxy-cyclopent-2-en-1-one derivatives are also disclosed.

  通式 I 的化合物是制备前列腺素的有用中间体： 其中 A 代表 0 或 H、ORz； Rz 代表氢或保护基团 Rx 代表氢或保护基团；以及 R2 代表直链或支链烷基、烯基或炔基，可任选被一个或多个羧基、羧酸酯或游离或保护羟基、硫醇、醛基或酮基取代；但条件是，当 A 为 O，Ry 为 R2 时，Rx 不是氢；当 A 为 H，ORz RY 为 R2 时，RX 和 Rz 都不是氢。 还公开了这些化合物和 2-取代的 4-羟基-环戊-2-烯-1-酮衍生物的制备方法。
• TW2016/2074
  申请人：——

  公开号：——

  公开（公告）日：——